Lancet Psychiatry:阿片类药物治疗慢性非癌性疼痛研究

2015-04-01 崔倩译 MedSci原创

比较了WHO的ICD-10和建议的ICD-11以及美国精神病学协会的DSM-IV和DSM-5对澳大利亚以社区为基础的慢性非癌性疼痛的样本进行分类。 方法 我们研究了疼痛和阿片类药物治疗(POINT)的群组参与者,一项在澳大利亚各地社区药店在2012-2013年招募的1514人的为期2年前瞻性群组研究。对患者进行他们使用阿片类药物的综合性国际诊断访谈后,我们评估了那些阿片类药物使用障碍的患者通过I

比较了WHO的ICD-10和建议的ICD-11以及美国精神病学协会的DSM-IV和DSM-5对澳大利亚以社区为基础的慢性非癌性疼痛的样本进行分类。

方法 我们研究了疼痛和阿片类药物治疗(POINT)的群组参与者,一项在澳大利亚各地社区药店在2012-2013年招募的1514人的为期2年前瞻性群组研究。对患者进行他们使用阿片类药物的综合性国际诊断访谈后,我们评估了那些阿片类药物使用障碍的患者通过ICD-10,  ICD-11, DSM-IV, 和DSM-5的分类。我们研究了分类系统间的一致性,并进行验证性因素分析的单维性综合征。

发现 我们共有1422个参与者(中位时间疼痛障碍10年[ IQR5~20 ] ;强阿片类药物的处方中位数为4年[IQR 1•5–10•0];平均年龄58岁)。人满足DSM-IV,ICD-10,ICD-11依赖一生标准的比例相似(127;8•9%),ICD-10(121;8 •5%),ICD-11(141;9•9%)。标准在DSM-5分类有127(8•9%)例是中度或重度障碍。ICD-10和DSM-IV依赖性诊断有良好的一致性(κ•> 0•90)。然而,在ICD-10和DSM-IV依赖性诊断之间只有中度一致性,DSM-5使用障碍(轻度,中度,重度)。只有在DSM-5中度到严重使用障碍和其他定义有很好的一致性。所有的定义都是在一个单因子标准下的;最好的模型拟合是依赖于草案ICD-11的定义,最糟糕的是在DSM-5中。

解释 ICD和DSM的版本有问题阿片类药物的分类有所不同。DSM-5和其他定义一致性水平比其他定义之间的水平要低得多,可能是由于DSM-5含有的标准数目的增加和治疗的依赖以及连续性有问题使用。更简洁的ICD-11依赖性定义表现出优异的模型拟合,并与以前的分类系统非常吻合。

原始出处

Prof Louisa Degenhardt, Raimondo Bruno, Nicholas Lintzeris.et.al.Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study.Lancet Psychiatry.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033100, encodeId=2704203310018, content=<a href='/topic/show?id=aa5053e132d' target=_blank style='color:#2F92EE;'>#慢性非癌性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53713, encryptionId=aa5053e132d, topicName=慢性非癌性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 19 12:55:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828048, encodeId=a922182804887, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 23 18:55:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819573, encodeId=3c0f18195e304, content=<a href='/topic/show?id=914f995e3a0' target=_blank style='color:#2F92EE;'>#非癌性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99573, encryptionId=914f995e3a0, topicName=非癌性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Wed Oct 07 23:55:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791909, encodeId=6fad1e91909a5, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Dec 07 09:55:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252989, encodeId=f02a1252989a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309000, encodeId=06a3130900007, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033100, encodeId=2704203310018, content=<a href='/topic/show?id=aa5053e132d' target=_blank style='color:#2F92EE;'>#慢性非癌性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53713, encryptionId=aa5053e132d, topicName=慢性非癌性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 19 12:55:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828048, encodeId=a922182804887, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 23 18:55:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819573, encodeId=3c0f18195e304, content=<a href='/topic/show?id=914f995e3a0' target=_blank style='color:#2F92EE;'>#非癌性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99573, encryptionId=914f995e3a0, topicName=非癌性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Wed Oct 07 23:55:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791909, encodeId=6fad1e91909a5, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Dec 07 09:55:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252989, encodeId=f02a1252989a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309000, encodeId=06a3130900007, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=)]
    2016-01-23 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033100, encodeId=2704203310018, content=<a href='/topic/show?id=aa5053e132d' target=_blank style='color:#2F92EE;'>#慢性非癌性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53713, encryptionId=aa5053e132d, topicName=慢性非癌性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 19 12:55:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828048, encodeId=a922182804887, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 23 18:55:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819573, encodeId=3c0f18195e304, content=<a href='/topic/show?id=914f995e3a0' target=_blank style='color:#2F92EE;'>#非癌性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99573, encryptionId=914f995e3a0, topicName=非癌性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Wed Oct 07 23:55:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791909, encodeId=6fad1e91909a5, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Dec 07 09:55:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252989, encodeId=f02a1252989a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309000, encodeId=06a3130900007, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033100, encodeId=2704203310018, content=<a href='/topic/show?id=aa5053e132d' target=_blank style='color:#2F92EE;'>#慢性非癌性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53713, encryptionId=aa5053e132d, topicName=慢性非癌性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 19 12:55:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828048, encodeId=a922182804887, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 23 18:55:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819573, encodeId=3c0f18195e304, content=<a href='/topic/show?id=914f995e3a0' target=_blank style='color:#2F92EE;'>#非癌性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99573, encryptionId=914f995e3a0, topicName=非癌性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Wed Oct 07 23:55:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791909, encodeId=6fad1e91909a5, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Dec 07 09:55:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252989, encodeId=f02a1252989a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309000, encodeId=06a3130900007, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033100, encodeId=2704203310018, content=<a href='/topic/show?id=aa5053e132d' target=_blank style='color:#2F92EE;'>#慢性非癌性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53713, encryptionId=aa5053e132d, topicName=慢性非癌性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 19 12:55:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828048, encodeId=a922182804887, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 23 18:55:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819573, encodeId=3c0f18195e304, content=<a href='/topic/show?id=914f995e3a0' target=_blank style='color:#2F92EE;'>#非癌性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99573, encryptionId=914f995e3a0, topicName=非癌性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Wed Oct 07 23:55:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791909, encodeId=6fad1e91909a5, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Dec 07 09:55:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252989, encodeId=f02a1252989a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309000, encodeId=06a3130900007, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2033100, encodeId=2704203310018, content=<a href='/topic/show?id=aa5053e132d' target=_blank style='color:#2F92EE;'>#慢性非癌性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53713, encryptionId=aa5053e132d, topicName=慢性非癌性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Mon Oct 19 12:55:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828048, encodeId=a922182804887, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jan 23 18:55:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819573, encodeId=3c0f18195e304, content=<a href='/topic/show?id=914f995e3a0' target=_blank style='color:#2F92EE;'>#非癌性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99573, encryptionId=914f995e3a0, topicName=非癌性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db7c233, createdName=changjitao2009, createdTime=Wed Oct 07 23:55:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791909, encodeId=6fad1e91909a5, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Mon Dec 07 09:55:00 CST 2015, time=2015-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252989, encodeId=f02a1252989a7, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309000, encodeId=06a3130900007, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Fri Apr 03 01:55:00 CST 2015, time=2015-04-03, status=1, ipAttribution=)]
    2015-04-03 lhlxtx

相关资讯

NEJM:全球阿片类药物滥用趋势分析报告

【1月26日讯】一项监测2002年—2013年间阿片类药物滥用趋势的研究显示,阿片类止痛药处方、阿片类转移和滥用以及阿片类相关死亡在2002年—2010年呈上升趋势。 然而,在2001年—2013年间上述三项测量指标呈平稳或下降的趋势。 “这表明美国对阿片类药物滥用作出了努力,而且干预措施确实见效了。”科罗拉多州丹佛卫生署及医院管理局药品中心主任、本研究的主要作者理查德·达特博士向

肠麻醉综合征的全新共识

引言 40%的成年人患有慢性疼痛,导致生活质量下降、工作时间缩短及相关的间接花费,如仅在美国每年由此导致的花费高达600亿美元。阿片类药物广泛应用于中至重度癌性及非癌性疼痛。现在临床医生、患者及社会统一认为缓解疼痛十分重要,因此阿片类药物的应用将会增加。如在美国,高达3%的成年人因慢性非癌性疼痛需服用阿片类药物镇痛治疗,每年有高达250,000,000份相关的处方 阿片类药物相

ERRM:阿片类药物治疗难治性呼吸困难

难治性呼吸困难是指在积极治疗原发病的前提下,在静息或轻微体力活动后仍出现呼吸困难症状。内源性(β- 内啡肽)和外源性(吗啡)阿片类药物可通过与阿片受体结合改善呼吸困难症状。 阿片类药物缓解难治性呼吸困难可能的机制包括:呼吸驱动联合伴随放电的减少、中枢感知的改变、肺部外周阿片类受体活性改变及焦虑症状改善。 由于患者对于阿片类药物的治疗效果不尽相同,一般从小剂量开始缓慢增加,直到达到病人认为能

孕期使用阿片类药物增加致畸风险

【1月26日讯】 今天,美国疾病控制和预防联邦卫生官员公布:“阿片类治疗疼痛药物在女性分娩时被广泛使用,是一个"严重的公众健康问题"”。 一项在1月13日发表于《发病率和死亡率周报 (MMWR)》 的研究显示,在2008至2012年间,约四分之一的被私人保险覆盖的女性,她们的年龄介于15—44岁之间;约三分之一的被医疗补助覆盖的患者每年都在按照阿片类处方服药。 “在孕期服用阿片类

JAAOS:长期使用阿片类药物患者骨科手术时的疼痛管理

阿片类药物在骨骼肌肉疼痛的临床治疗中应用较多。但是,阿片药物使用较长时间较多的副作用,对有长期阿片类药物使用病史的患者,围手术期的疼痛控制是一个难点。 对这类患者需进行仔细的评估,包括术前患者的阿片类药物使用量,患者对疼痛相关的敏感程度,是否有潜在的精神或心理疾病等。对大剂量使用阿片药物的患者,需请专科医生评估是否存在成瘾性的可能。多种局部阻滞麻醉和药物止痛方法可以用来改善围手术期疼痛,

JAMA:服用阿片类药物的老年患者住院率连年升高

卫生保健研究与质量管理局(AHRQ)研究了1993年到2012年服用阿片类止疼药的成人住院率情况,结果发现,85岁及以上患者住院率居首位,65~84岁患者位居第二,45~64岁患者位居第三。而且,医疗保险的理赔也随此住院率迎来最大的增长率,占所有住院治疗的30%,这是1993年的一倍。 这是一个重要的公共卫生问题 NIH的官员指出,对于阿片类药物,特别是老年患者,已经出现过度依赖的状况